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AbstrAct
Objective To determine medical needs, demographic 
characteristics and healthcare utilisation patterns of the 
top 1% and top 2%–5% high-cost beneficiaries in the 
Netherlands.
Design Cross-sectional study using 1 year claims data. 
We broke down high-cost beneficiaries by demographics, 
the most cost-incurring condition per beneficiary and 
expensive treatment use.
setting Dutch curative health system, a health system 
with universal coverage.
Participants 4.5 million beneficiaries of one health 
insurer.
Measures Annual total costs through hospital, intensive 
care unit use, expensive drugs, other pharmaceuticals, 
mental care and others; demographics; most cost-
incurring and secondary conditions; inpatient stay; number 
of morbidities; costs per ICD10-chapter (International 
Statistical Classification of Diseases, 10th revision); and 
expensive treatment use (including dialysis, transplant 
surgery, expensive drugs, intensive care unit and 
diagnosis-related groups >€30 000).
results The top 1% and top 2%–5% beneficiaries 
accounted for 23% and 26% of total expenditures, 
respectively. Among top 1% beneficiaries, hospital care 
represented 76% of spending, of which, respectively, 
9.0% and 9.1% were spent on expensive drugs and ICU 
care. We found that 54% of top 1% beneficiaries were 
aged 65 years or younger and that average costs sharply 
decreased with higher age within the top 1% group. 
Expensive treatments contributed to high costs in one-
third of top 1% beneficiaries and in less than 10% of top 
2%–5% beneficiaries. The average number of conditions 
was 5.5 and 4.0 for top 1% and top 2%–5% beneficiaries, 
respectively. 53% of top 1% beneficiaries were treated 
for circulatory disorders but for only 22% of top 1% 
beneficiaries this was their most cost-incurring condition.
conclusions Expensive treatments, most cost-
incurring condition and age proved to be informative 
variables for studying this heterogeneous population. 
Expensive treatments play a substantial role in high-
costs beneficiaries. Interventions need to be aimed at 
beneficiaries of all ages; a sole focus on the elderly would 
leave many high-cost beneficiaries unaddressed. Tailored 
interventions are needed to meet the needs of high-cost 
beneficiaries and to avoid waste of scarce resources.
IntrODuctIOn
It is known that healthcare costs are concen-
trated among small numbers of ‘high-cost’ 
beneficiaries. These high-cost beneficiaries 
are the sickest and most complex populations. 
Although they receive substantial care from 
multiple sources, critical healthcare needs 
are often unmet, and many receive unneces-
sary and ineffective care.1–4 Therefore, high-
cost beneficiaries are a useful group on which 
to focus efforts of quality improvement and 
cost containment.
For effective quality improvement and 
cost reduction, it is necessary to acquire an 
in-depth understanding of the characteris-
tics, healthcare use and other factors that 
drive the costs of these groups of high-cost 
beneficiaries.5 6 Current literature suggests 
that a high prevalence of multiple (chronic) 
conditions may explain high-cost benefi-
ciaries’ excessive care use.7 8 This presence 
of multimorbidity among high-cost benefi-
ciaries makes them difficult to understand: 
how to characterise patients that suffer from 
several diseases? Lehnert et al9 found that the 
number of chronic comorbidities were nearly 
exponentially related to costs: the higher the 
number of chronic comorbidities, the higher 
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Research
strengths and limitations of this study
 ► This study presents an in-depth analysis of the 
medical needs, demographics and healthcare 
utilisation of high-cost beneficiaries in the 
Netherlands.
 ► We characterised high-cost beneficiaries and 
spending patterns using several variables, including 
expensive treatment use (eg, dialysis, expensive 
drugs and intensive care unit), most cost-incurring 
condition and age.
 ► Analyses were limited to one large insurer, but its 
beneficiaries are representative for the Netherlands.
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Figure 1 Cost drivers per age group in top 1% 
beneficiaries.
the costs of an additional comorbidity. Based on this study, 
we hypothesised that in high-cost beneficiaries the most 
cost-incurring condition accounts for a disproportionate 
share of costs and that secondary conditions account for 
the remainder of costs.
A major limitation of current literature is that little 
is known about patterns in care use and characteristics 
among different age groups.10 In addition, until today, 
no studies have reported the role of expensive treatments 
(eg, expensive drugs, transplant surgery, intensive care 
units (ICUs) and dialysis) as drivers of high costs. Further 
insight in healthcare utilisation patterns is needed to 
develop interventions and inform policy aimed at high-
need, high-cost populations.
The primary aim of this study was to determine medical 
needs, demographic characteristics and healthcare utili-
sation patterns of high-cost beneficiaries in the Nether-
lands. We first determined characteristics and spending 
and quantified the share of high-cost beneficiaries that 
use expensive treatments. We then used a beneficia-
ry’s most cost-incurring medical condition to examine 
characteristics and utilisation patterns. In addition, we 
compared utilisation and conditions across age groups. 
All analyses were performed for top 1% and top 2%–5% 
beneficiaries separately. This distinction is often used in 
literature11–14 and may improve understanding of high-
cost beneficiaries.
MethODs
Design and context
We conducted an cross-sectional study using claims data 
from 2013 in the Netherlands. In the Netherlands, the 
Health Insurance Act legally requires health insurers to 
provide a nationally set benefits package. Nearly universal 
coverage for curative care is achieved through mandatory 
purchase of statutory private health insurance.15 16 Anal-
yses were done in-house with Zilveren Kruis, a health 
insurer covering 4.5 million beneficiaries who were 
primarily living in the central, eastern and western parts 
of the Netherlands. The basic principle of the Dutch 
curative health system is that insurers compete for bene-
ficiaries and that they act as prudent buyers of services 
for their beneficiaries. Health insurers operate nation-
wide, are obliged to accept all applicants for basic health 
plans and are not permitted to risk-rate premiums for 
these basic plans. Every insured person, aged 18 years or 
older, is required to pay an annual deductible (€350 in 
2013), from which some services, such as general prac-
tice visits, are excluded. In addition to the basic health 
plan, more than 80% of the population buys voluntary 
insurance. Premiums for voluntary insurance are not 
regulated, and insurers are allowed to screen applicants. 
The system provides a wide range of services, including 
care provided by general practitioners, hospitals and 
specialists, dental care through age 18 years, prescription 
drugs, physiotherapy through age 18 years, most mental 
care, medical aids and devices, maternity care, transpor-
tation and others. In our study, we also included private 
voluntary supplementary insurance that typically covers 
dental care, some allied healthcare (including physio-
therapy, occupational therapy, dietary advice and speech 
therapy) and complementary medicine (typically homoe-
opathy, acupuncture, natural medicine, magnetising and 
osteopathy).
Data
All insured in 2013 were included in this study. Several 
beneficiary characteristics were obtained from the insur-
er’s databases, including gender, socioeconomic status 
based on income estimates per postal code, date of birth 
and date of death (until 20 February 2015). Date of death 
was categorised to four quarters in 2013 and any date 
post-2013. More information about (a predecessor of) 
this database is provided in Smeets et al.17
Total costs per beneficiary were calculated by summing 
all claims with a starting date in 2013. We defined the 
beneficiaries with the top 1% and the top 2%–5% of 
total costs as two groups of high-cost beneficiaries. The 
remaining 95% were categorised as low-cost benefi-
ciaries. All claims were categorised in nine cost groups 
(health sectors) using a link table provided by the Dutch 
Healthcare Institute. These sectors included: hospital 
care (including care used abroad), mental healthcare, 
primary care, maternal care, allied healthcare, outpatient 
pharmaceutical prescriptions, medical devices, dental 
care (most dental care is reimbursed through comple-
mentary insurance benefits) and voluntary complemen-
tary insurance benefits.
Below, we describe how we operationalised the variables 
that we included in our analysis, including the treatment 
costs per diagnosis, the prevalence of conditions and 
multimorbidity count and the use of specific (expensive) 
services.
Treatment cost per diagnosis
We categorised and analysed hospital and mental care 
costs, according to the International Statistical Classifi-
cation of Diseases, 10th revision (ICD-10).18 Treatment 
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costs were categorised to the level of ICD-10 chapters 
(eg, chapter IX: diseases of the circulatory system) and 
ICD-10 subchapters (eg, subchapter I60–I69 cerebrovas-
cular diseases).
The great majority of hospital care in the Netherlands 
is reimbursed through payment products similar to diag-
nosis-related groups (DRGs, which cover both inpatient 
and outpatient hospital care) and so-called add-ons for 
expensive drugs and treatment at the ICU. To compute 
treatment costs per diagnosis, the DRGs were categorised 
using a link table provided by the Dutch Health Care 
Authority. This link table (version 22 December 2014) 
was developed to categorise hospital claims to specific 
healthcare needs, following the ICD-10 classification.18 
For the purpose of our study, we made a few minor correc-
tions to the link table. As we found the ICD subchapter 
I30–I52 (other circulatory diseases) highly prevalent but not 
informative, we decided to disaggregate this subchapter. 
Add-ons were not used for establishing treatment cost per 
diagnosis but are dealt with separately (see ‘use of specific 
expensive services’).
In 2013, the Dutch mental care sector consisted of 
‘primary’ mental care, such as care provided at general 
practices, by psychologists and psychotherapists, and at 
‘secondary’ or specialised mental care provided in mental 
care institutions. Only claims from secondary mental 
healthcare were used for characterisation as these specify 
information about diagnoses and treatment. These claims 
were categorised to the ICD-10 (sub)chapter and added 
to the hospital claims for ICD-10 chapter V: mental and 
behavioural disorders. Additionally, the number of inpa-
tients days in mental care per beneficiary was calculated 
(but not used for establishing treatment cost).
Prevalence of conditions and multimorbidity count
Prevalence of conditions was established using the same 
categorisation as described above. In addition, we used 
parameters from the Dutch risk adjustment scheme: 
pharmaceutical cost groups that indicate chronic use of 
drugs for different conditions. These pharmaceutical 
cost groups were categorised to ICD-10 (sub-)chapters 
and integrated with the former to establish prevalence 
of conditions. A detailed description of the Dutch risk 
adjustment scheme is provided in van Veen.19 Multi-
morbidity was operationalised in three ways. First, multi-
morbidity was calculated by counting the number of 
prevalent ICD-10 chapters per beneficiary. Second, we 
counted the number of prevalent ICD-10 subchapters per 
beneficiary. Third, the number of pharmaceutical cost 
groups was counted, reflecting the number of chronic 
multimorbidities.
Use of specific (expensive) services
We developed dummy variables for specific types of care. 
Beneficiaries were regarded ‘expensive care users’ if their 
claims included a minimum of €10 000 for ‘add-ons’ for 
ICU treatment or expensive drugs. We used €10 000 as 
threshold because in 2013 expensive drugs only qualified 
for add-on reimbursement when average yearly costs per 
beneficiary exceeded this value. ICU treatment as reim-
bursed through add-ons included ICU treatment days, 
ICU consultations, ICU surcharges for specific services, 
ICU neonatal and paediatric care and ICU transport 
services such as interclinical transportation services and 
mobile intensive care unit. Expensive drugs reimbursed 
through add-ons included growth hormones, antineo-
plastic agents, tumour necrosis factor-alpha inhibitors, 
orphan drugs, haemostatics and other expensive drugs.20 
The list of drugs and indications that qualify for add-on 
reimbursement can be found at www. farmatec. nl
A separate dummy variable ‘transplant’ was developed, 
for beneficiaries who received a transplant or trans-
plant-related care (both pretransplant and post-trans-
plant). One DRG description that included the word 
‘transplant’ was sufficient for a person to qualify as trans-
plant beneficiary. Similarly, the variable ‘dialysis’ was 
created for all beneficiaries receiving dialysis for renal 
failure (both peritoneal and haemodialysis). In addition, 
all DRGs with an average price >€30 000 were identified 
and together included as separate binary variable. This 
price was chosen as all top 1% beneficiaries incurred 
€30 000 or more. Furthermore, two dummy variables for 
mental health use were computed, the first on mental 
care use (>€0 mental care costs) and the second on 
inpatient stays (>0 days). The total number of inpatient 
hospital days per beneficiary was estimated using national 
averages of hospital days per DRG.21 Finally, we used 
claims data to derive the number of different hospitals, 
university medical centres and hospital specialisms that 
beneficiaries were treated at, as well as the number of 
ambulance transportations, and emergency department 
visits. For full details concerning the variable computa-
tion, please contact the corresponding author.
Analyses
We explored the composition of expenditures across 
health sectors for both top 1% and top 2%–5% beneficia-
ries. Demographics, medical characteristics and (expen-
sive) healthcare use were analysed using descriptive 
statistics.
Most cost-incurring and secondary conditions
For each high-cost beneficiary, we identified the most 
cost-incurring ICD-10 (sub)chapter. For both top 1% 
and top 2%–5% beneficiaries, we first determined the 
prevalence of each ICD-10 subchapter. Second, for both 
high-cost groups we summed treatment cost per ICD-10 
subchapter and divided this with the sum of total costs. 
Third, for each ICD-10 subchpater, we calculated how 
frequently it was the most cost-incurring condition for 
the beneficiaries in these groups. Fourth, we divided the 
percentage of beneficiaries with a ICD-10 subchapter as 
the most cost-incurring condition by the overall preva-
lence of the ICD-10 subchapter. This metric was used to 
distinguish between ICD-10 subchapters that were mainly 
found as most cost-incurring conditions compared with 
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ICD-10 subchapters that were mainly found as secondary 
conditions. Fifth, for each beneficiary, we divided the 
treatment cost for the most cost-incurring condition 
by total costs. This figure was averaged for each ICD-10 
subchapter and determines the contribution of these 
conditions to total costs within the subpopulation.
Healthcare use according to most cost-incurring ICD-10 chapter 
and across age groups
To identify patterns in (expensive) healthcare use, we 
developed cross-tables with costs per ICD-10 chapter, 
(expensive) healthcare use indicators and demographic 
characteristics as descriptive variables. Beneficiaries were 
selected by the most cost-incurring ICD-10 chapter to 
prevent that beneficiaries with multimorbidity would be 
counted several times.
Finally, we compared utilisation patterns and conditions 
across age groups. We examined total costs and spending 
per sector, and we identified the five most cost-incurring 
ICD-10 chapters per age group.
All analyses were performed using SAS V.9.4, Enter-
prise Guide 6.1.
results
General breakdown of costs
Average total costs for top 1%, top 2%–5% and bottom 
95% beneficiaries were €56 424, €15 780 and €1345, 
respectively, representing 22.8%, 25.5% and 51.7% 
of total spending (table 1). For top 1% beneficiaries, 
hospital care represented 76% of costs, of which, respec-
tively, 9.0% and 9.1% were for expensive drugs and ICU 
care. 12.7% and 6.6% of costs were for mental healthcare 
and outpatient pharmaceuticals, respectively. For top 
2%–5% beneficiaries, hospital care represented 59.7% of 
spending, of which 6.0% and 2.1% were spent on expen-
sive drugs and ICU care, while 9.8% and 11.2% were spent 
on mental healthcare and outpatient pharmaceuticals.
Demographics and (expensive) healthcare use
Table 1 presents demographic and medical characteristics 
of the study population as well as (expensive) healthcare 
use. Males were over-represented among top 1% bene-
ficiaries, and females were over-represented among top 
2%–5% beneficiaries. Top 1% and top 2%–5% beneficia-
ries were much older than low-cost beneficiaries. Further-
more, high-cost beneficiaries were more likely to die: 
9.9% and 6.1% of top 1% and top 2%–5% beneficiaries 
died. However, 63.7% of beneficiaries in our study who 
died in 2013 or later did not incur high costs in 2013. The 
average number of morbidities based on ICD-10 subchap-
ters for top 1%, top 2%–5% and bottom 95% beneficia-
ries was 5.5, 4.0 and 0.8, respectively.
Table 1 also shows that top 1% and top 2%–5% 
beneficiaries scored higher than low-cost users for 
each specific service, and top 1% beneficiaries scored 
higher than top 2%–5% beneficiaries. Both top 1% and 
top 2%–5% beneficiaries used on average one type of 
drugs (pharmaceutical cost groups) continuously. A 
percentage of 24.8 of top 1% and 5.8% of top 2%–5% 
beneficiaries incurred more than €10 000 on expensive 
drugs and ICU. Furthermore, 6.1% of top 1% benefi-
ciaries underwent dialysis and 3.7% received transplant 
care. Top 1% and top 2%–5% beneficiaries were treated 
in on average 1.9 and 1.6 hospitals, and used on average 
22 and 7 inpatient days, respectively. Finally, 13% and 
3.3% of top 1% and top 2%–5% beneficiaries were 
admitted to mental care institutions, respectively.
utilisation according to IcD-10 subchapters and most cost-
incurring and secondary conditions,
 Online appendix 1 presents five parameters for both 
high-cost populations. Among those in the top 1%, 
a high prevalence of several cardiovascular diseases, 
chronic obstructive pulmonary disease, diabetes 
mellitus and depression were found. In addition, the 
total treatment costs for renal insufficiency (including 
dialysis) were much higher than for any other ICD-10 
subchapter and accounted for 6.8% of total costs 
among top 1% beneficiaries. We use table 2, with a 
selection of 10 ICD-10 subchapters in top 1% benefi-
ciaries, to illustrate the other parameters for top 1% 
beneficiaries. Renal insufficiency, certain cancers and 
several cardiovascular diseases were frequently found 
as the most cost-incurring condition among top 1% 
beneficiaries. Furthermore, for beneficiaries that 
were treated for cancer, the cancer itself was in most 
cases the most cost-incurring condition (eg, 74.3% of 
beneficiaries with leukaemia). In contrast, circulatory 
disorders were mainly found as secondary condition: 
for example, in less than 30% of patients with isch-
aemic heart disease or heart failure, this was their most 
cost-incurring condition. Finally, we determined the 
contribution of ICD-10 subchapters towards total costs 
per beneficiary. The most cost-incurring condition 
accounted for 40%–70% of total costs per beneficiary, 
depending on the ICD-10 subchapter.
utilisation according to most cost-incurring IcD-10 chapter
Table 3 and online appendix 2 show cross-tables for 
spending, demographics and indicators for (expensive) 
healthcare use. In these analyses, beneficiaries were 
selected by most cost-incurring ICD-10 chapter to avoid 
multimorbid beneficiaries being analysed on multiple 
rows. Among top 1% beneficiaries, three ICD-10 chap-
ters were frequently found as most cost-incurring ICD-10 
chapter: mental or behavioural disorders, neoplasms and 
diseases of the circulatory system. These groups had quite 
different characteristics and utilisation. Beneficiaries with 
mental or behavioural disorders were relatively young, 
had a low number of morbidities and low mortality. Bene-
ficiaries with neoplasms were the largest subgroup with 
high mortality. Beneficiaries with diseases of circulatory 
system were oldest (on average 69 years old) and predom-
inantly men. Expensive drugs were heavily concentrated 
among beneficiaries with neoplasms. ICU costs were 
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Table 1 General characteristics and indicators for healthcare use for three distinct cost groups
General characteristics Top 1% Top 2%–5% Bottom 95%
Number of beneficiaries 45 207 180 826 4 294 611
Average total costs (SD) €56 424
(€40 830)
€15 780
(€5208)
€1345
(€1773)
Share of total costs (%) 22.8 25.5 51.7
Private spending* (SD) €330 (€172) €335 (€165) €159 (€181)
Gender (%)
  Male 52.3 44.8 49.6
  Female 47.7 55.2 50.4
Mean age (SD) 58.5 (21.6) 58.0 (21.8) 39.2 (23.3)
Median age (years) 64 62 39
Percentage dying in or after study period (%)
  Q1: 0.7 0.9 0.2
  Q2: 1.8 1.6 0.2
  Q3: 3.2 1.7 0.1
  Q4: 4.2 1.9 0.1
  >Q4†: 12.5 5.9 0.7
Socioeconomic status (%)
  >15 inhabitants‡ 4.5 3.1 1.0
  Lowest incomes: 31.1 31.5 31.4
  Average income: 37.5 38.5 37.7
  High income: 26.8 26.7 28.6
Medical characteristics Top 1% Top 2%–5% Bottom 95%
Average number of comorbidities—ICD chapter (SD) 4.2 (2.1) 3.3 (1.8) 0.7 (1.1)
Average number of comorbidities—ICD subchapter (SD) 5.5 (3.1) 4.0 (2.3) 0.8 (1.2)
Average number of chronic comorbidities—calculated by 
pharmaceutical cost groups (SD)
1.1 (1.2) 1.0 (1.1) 0.2 (0.6)
(Expensive) healthcare use Top 1% Top 2%–5% Bottom 95%
Percentage using expensive care >€10 000 (%) 24.6 5.8 0.0
Percentage transplant beneficiaries (%) 3.7 0.8 0.03
Percentage receiving dialysis (%) 6.1 0.1 0.0
Percentage receiving DRG >€30 000 (%) 4.5 0.03 0
Percentage with >0 inpatient mental healthcare stays (%) 13.0 3.3 0.04
Percentage with mental healthcare costs >€0 (%) 23.5 20.6 6.4
Average number of inpatient mental hospital days (SD)§ 54.7 (74.3) 4.0 (11.7) 0.05 (0.8)
Percent visiting a specialised mental care centre (%) 22.5 19.2 4.8
Average number of hospital specialists involved (SD) 4.2 (2.3) 3.0 (1.8) 0.6 (1.0)
Average number of hospitals visited (SD) 1.9 (1.0) 1.6 (0.9) 0.5 (0.7)
Average number of inpatient hospital days (SD) 22.3 (26.0) 7.2 (8.4) 0.4 (1.5)
Percentage using care at a university hospital (%) 39.7 25.8 4.5
Average number of ambulance transportations (SD) 1.4 (4.3) 0.5 (1.0) 0.02 (0.17)
Average number of emergency department visits (SD) 0.7 (1.4) 0.4 (0.7) 0.07 (0.27)
*Consisting of the compulsory deductible of €350.
†Dates of death were recorded until the 20 February 2015.
‡ Most of whom are institutionalised.
§ For those with mental healthcare costs >€0.
DRG, diagnosis-related groups; ICD, International Statistical Classification of Diseases.
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Table 2 Ten conditions with highest total costs among top 1% beneficiaries
Prevalence (%)*
% of total 
costs†
% as most 
cost-
incurring 
condition‡
% most cost-
incurring/
prevalence§
% of costs by most 
cost-incurring 
condition¶
N17-N19 Renal failure 12.2 6.8 6.4 52.4 66.0
C81-C96 Leukaemia 5.6 3.0 4.1 74.3 41.4
C15-C26 Malignant 
neoplasms of digestive 
organs
7.5 2.4 5.4 71.2 47.9
I60-I69 Cerebrovascular 
diseases
7.9 2.1 4.2 53.1 52.7
I70-I79 Diseases of arteries, 
arterioles and capillaries
9.6 2.0 4.1 42.7 47.3
C30-C39 Lung cancer 5.9 1.7 3.5 59.1 52.5
I51-I52 Complications/ill-
defined descriptions, other 
heart disorders
9.6 1.6 3.2 33.1 50.3
I44–I49 Atrial fibrillation, 
rhythm and conduction 
disorders
11.8 1.6 2.9 24.3 58.5
I20-I25 Ischaemic heart 
diseases
12.7 1.6 3.7 29.0 41.9
I50 Heart failure 9.3 1.5 2.6 28.4 57.1
*Prevalence of each ICD-10 subchapter among top 1% beneficiaries. For example, 12.2% of top 1% beneficiaries were treated for renal 
failure.
†Sum of total treatment costs per ICD-10 subchapter. For example, treatment of renal failure accounted for 6.8% of total expenditures of top 
1% beneficiaries.
‡Percentage of top 1% with this ICD-10 subchapter as most cost-incurring condition. For example, 6.4% of top 1% beneficiaries had renal 
failure as most cost-incurring condition.
§Percentage most cost-incurring condition relative to prevalence: fourth column divided by second column. For example, for 52.4% of top 
1% beneficiaries who were treated for renal failure, this was also their most cost-incurring condition.
¶Percentage of costs accounted for by the most cost-incurring condition. For example, among top 1% beneficiaries with renal failure as most 
cost-incurring condition, this disease accounted for on average 66% of total costs per beneficiary.
distributed more proportionally; a quarter was incurred 
by beneficiaries with circulatory diseases.
Among top 2%–5% beneficiaries, the same three most 
cost-incurring ICD-10 chapters predominated, although 
they represented a smaller share of the group. Several 
other ICD-10 chapters had relatively high costs, including 
diseases of the digestive system; injury, poisoning and 
certain other consequences of external causes (femur 
fracture most prominently); and diseases of the muscu-
loskeletal system and connective tissue. Beneficiaries with 
neoplasms, diseases of the respiratory system and symp-
toms, signs and abnormal clinical and laboratory findings 
most frequently died. Expensive drugs were primarily 
used by beneficiaries with diseases of the musculoskeletal 
system (rheumatoid arthritis), neoplasms and diseases of 
the digestive system.
healthcare use across age groups
This Figure 1 and online appendix 3 provide an overview 
of cost segments per age category among top 1% and 
top 2%–5% beneficiaries. With the exception of infants, 
treatment at the ICU represented a maximum of 10% 
of costs per age group. Moreover, treatment at the ICU 
represented a major cost driver primarily among top 1% 
beneficiaries. The proportion of costs spent on expensive 
drugs was highest (13.4% of total costs) among top 1% 
beneficiaries between 21 and 30 years old. Mental care 
accounted for a large share of costs among children and 
young and middle-aged adults. The percentage of cost 
incurred by outpatient and non-expensive pharmaceuti-
cals was more pronounced among top 2%–5% beneficia-
ries than among top 1% beneficiaries.
Table 4 and online appendix 4 present the five ICD-10 
chapters with highest total costs per age group for top 
1% and top 2%–5% beneficiaries. As mentioned before, 
we found that high-cost beneficiaries are generally older 
than low-cost beneficiaries. However, table 4 shows that 
within the top 1% beneficiaries average costs decreased 
with higher age: average costs ranged from €47 000 on 
average for top 1% beneficiaries over 80 years of age to 
>€80 000 on average for infants. In addition, 54% of top 
1% and 57% of top 2%–5% beneficiaries were 65 years of 
age or younger.
group.bmj.com on February 5, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Wammes JJG, et al. BMJ Open 2017;7:e017775. doi:10.1136/bmjopen-2017-017775
Open Access
Ta
b
le
 3
 
C
ro
ss
-t
ab
le
 d
es
cr
ib
in
g 
p
at
te
rn
s 
of
 h
ea
lth
ca
re
 u
se
 a
nd
 d
em
og
ra
p
hi
cs
 o
f t
op
 1
%
 b
en
efi
ci
ar
ie
s
IC
D
-1
0 
ch
ap
te
r
P
re
va
le
nc
e 
(%
)*
%
 m
o
st
 c
o
st
-
in
cu
rr
in
g
 IC
D
-1
0 
ch
ap
te
r
A
ve
ra
g
e 
ag
e 
(y
ea
rs
)
P
er
ce
nt
ag
e 
d
yi
ng
P
er
ce
nt
ag
e 
m
en
A
ve
ra
g
e 
nu
m
b
er
 o
f 
co
m
o
rb
id
it
ie
s 
(IC
D
- 
ch
ap
te
r)
A
ve
ra
g
e 
co
st
(*
€1
00
0)
E
xp
en
si
ve
 
d
ru
g
s 
(*
€1
00
0)
In
te
ns
iv
e 
ca
re
 
(*
€1
00
0)
N
eo
p
la
sm
(*
€1
00
0)
M
en
ta
l a
nd
 
b
eh
av
io
ur
al
 
d
is
o
rd
er
s 
(*
€1
00
0)
D
is
ea
se
s 
ci
rc
ul
at
o
ry
 
sy
st
em
 
(*
€1
00
0)
D
is
ea
se
s 
g
en
it
o
ur
in
ar
y 
sy
st
em
(*
€1
00
0)
C
er
ta
in
 in
fe
ct
io
us
 a
nd
 
p
ar
as
iti
c 
d
is
ea
se
s
10
.2
1.
0
60
.3
16
.8
60
.4
5.
5
54
25
15
34
07
40
7
24
7
38
2
40
0
N
eo
p
la
sm
s
36
.8
23
.2
62
.0
16
.4
49
.5
3.
9
56
11
1 
92
7
27
 7
34
29
5 
90
2
20
62
76
29
49
91
D
is
ea
se
s 
of
 t
he
 b
lo
od
 a
nd
 
b
lo
od
-f
or
m
in
g 
or
ga
ns
 a
nd
 
ce
rt
ai
n 
d
is
or
d
er
s 
in
vo
lv
in
g 
th
e 
im
m
un
e 
m
ec
ha
ni
sm
4.
4
1.
0
42
.1
3.
7
65
.9
3.
3
10
3
33
 5
35
53
1
14
3
62
21
3
91
E
nd
oc
rin
e,
 n
ut
rit
io
na
l a
nd
 
m
et
ab
ol
ic
 d
is
ea
se
s
21
.5
1.
3
39
.2
6.
1
49
.2
4.
0
67
84
52
30
25
19
1
22
8
43
2
22
4
M
en
ta
l a
nd
 b
eh
av
io
ur
al
 
d
is
or
d
er
s
32
.2
14
.7
41
.1
1.
2
51
.8
2.
7
55
44
87
42
92
84
1
13
5  
43
1
17
46
78
7
D
is
ea
se
s 
of
 t
he
 n
er
vo
us
 
sy
st
em
29
.3
2.
6
54
.7
8.
4
52
.2
4.
6
56
93
03
61
85
84
5
68
2
10
64
44
2
D
is
ea
se
s 
of
 t
he
 e
ye
 a
nd
 
ad
ne
xa
18
.2
0.
2
62
.4
1.
1
43
.6
4.
0
47
97
4
11
2
45
15
13
9
D
is
ea
se
s 
of
 t
he
 e
ar
 a
nd
 
m
as
to
id
 p
ro
ce
ss
5.
4
0.
3
44
.5
1.
6
48
.8
3.
4
60
20
0
23
2
25
14
59
23
D
is
ea
se
s 
of
 t
he
 
ci
rc
ul
at
or
y 
sy
st
em
52
.8
22
.3
68
.7
9.
5
60
.9
4.
6
49
75
64
63
 6
68
59
92
25
19
26
9 
39
4
47
09
D
is
ea
se
s 
of
 t
he
 
re
sp
ira
to
ry
 s
ys
te
m
24
.1
4.
4
62
.8
16
.7
48
.9
4.
8
53
52
58
20
 2
04
18
65
80
1
26
28
80
1
D
is
ea
se
s 
of
 t
he
 d
ig
es
tiv
e 
sy
st
em
20
.0
4.
0
55
.2
12
.0
51
.2
4.
7
55
10
 3
59
19
 3
43
17
17
87
3
15
23
10
13
D
is
ea
se
s 
of
 t
he
 s
ki
n 
an
d
 
su
b
cu
ta
ne
ou
s 
tis
su
e
10
.0
0.
5
59
.5
7.
2
48
.3
4.
8
51
13
71
10
09
10
3
60
23
4
82
D
is
ea
se
s 
of
 t
he
 
m
us
cu
lo
sk
el
et
al
 s
ys
te
m
 
an
d
 c
on
ne
ct
iv
e 
tis
su
e
19
.4
4.
1
66
.0
4.
1
34
.8
4.
8
47
10
 7
50
31
04
10
90
86
2
23
59
69
9
D
is
ea
se
s 
of
 t
he
 
ge
ni
to
ur
in
ar
y 
sy
st
em
24
.4
7.
2
63
.4
10
.5
58
.0
5.
2
82
50
00
12
 3
07
25
46
69
1
89
21
17
1 
36
0
P
re
gn
an
cy
, c
hi
ld
b
irt
h 
an
d
 
th
e 
p
ue
rp
er
iu
m
0.
5
0.
2
31
.0
0.
0
0.
0
3.
8
44
15
9
18
2
8
60
28
18
C
er
ta
in
 c
on
d
iti
on
s 
or
ig
in
at
in
g 
in
 t
he
 p
er
in
at
al
 
p
er
io
d
0.
1
0.
0
0.
2
0.
0
60
.0
6.
0
23
9
1
87
4
1
4
13
0
C
on
ge
ni
ta
l m
al
fo
rm
at
io
ns
, 
d
ef
or
m
at
io
ns
 a
nd
 
ch
ro
m
os
om
al
 
ab
no
rm
al
iti
es
3.
1
0.
7
8.
2
6.
3
54
.3
3.
6
73
12
62
92
30
9
69
28
5
51
S
ym
p
to
m
s,
 s
ig
ns
 a
nd
 
ab
no
rm
al
 c
lin
ic
al
 a
nd
 
la
b
or
at
or
y 
fin
d
in
gs
, n
ot
 
el
se
w
he
re
 c
la
ss
ifi
ed
49
.2
2.
1
55
.4
14
.1
50
.8
4.
6
60
98
24
90
86
48
2
46
0
10
34
38
7 C
on
tin
ue
d
group.bmj.com on February 5, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Wammes JJG, et al. BMJ Open 2017;7:e017775. doi:10.1136/bmjopen-2017-017775
Open Access 
IC
D
-1
0 
ch
ap
te
r
P
re
va
le
nc
e 
(%
)*
%
 m
o
st
 c
o
st
-
in
cu
rr
in
g
 IC
D
-1
0 
ch
ap
te
r
A
ve
ra
g
e 
ag
e 
(y
ea
rs
)
P
er
ce
nt
ag
e 
d
yi
ng
P
er
ce
nt
ag
e 
m
en
A
ve
ra
g
e 
nu
m
b
er
 o
f 
co
m
o
rb
id
it
ie
s 
(IC
D
- 
ch
ap
te
r)
A
ve
ra
g
e 
co
st
(*
€1
00
0)
E
xp
en
si
ve
 
d
ru
g
s 
(*
€1
00
0)
In
te
ns
iv
e 
ca
re
 
(*
€1
00
0)
N
eo
p
la
sm
(*
€1
00
0)
M
en
ta
l a
nd
 
b
eh
av
io
ur
al
 
d
is
o
rd
er
s 
(*
€1
00
0)
D
is
ea
se
s 
ci
rc
ul
at
o
ry
 
sy
st
em
 
(*
€1
00
0)
D
is
ea
se
s 
g
en
it
o
ur
in
ar
y 
sy
st
em
(*
€1
00
0)
In
ju
ry
, p
oi
so
ni
ng
 
an
d
 c
er
ta
in
 o
th
er
 
co
ns
eq
ue
nc
es
 o
f e
xt
er
na
l 
ca
us
es
22
.3
6.
8
71
.5
9.
7
39
.5
4.
7
50
29
86
15
 1
69
18
13
17
89
56
68
10
55
Fa
ct
or
s 
in
flu
en
ci
ng
 h
ea
lth
 
st
at
us
 a
nd
 c
on
ta
ct
 w
ith
 
he
al
th
 s
er
vi
ce
s
31
.7
3.
6
30
.5
2.
1
55
.3
3.
9
67
34
17
30
 9
51
13
88
44
7
32
34
63
6
*P
re
va
le
nc
e 
of
 IC
D
-1
0 
ch
ap
te
rs
 a
m
on
g 
th
e 
to
ta
l p
op
ul
at
io
n.
 A
ll 
ot
he
r 
co
lu
m
ns
 a
p
p
ly
 fo
r 
b
en
efi
ci
ar
ie
s 
w
ith
 t
he
 s
el
ec
te
d
 m
os
t 
co
st
-i
nc
ur
rin
g 
IC
D
-1
0 
ch
ap
te
r 
p
er
 r
ow
.
IC
D
, I
nt
er
na
tio
na
l S
ta
tis
tic
al
 C
la
ss
ifi
ca
tio
n 
of
 D
is
ea
se
s.
Ta
b
le
 3
 
C
on
tin
ue
d
 
For each age group, there were different ICD-10 chap-
ters with highest costs. Among top 1% beneficiaries, 
cardiovascular diseases and diseases of the genitouri-
nary system gained importance with higher age, whereas 
mental and behavioural disorders predominated among 
younger and middle-aged beneficiaries. Among top 
2%–5% beneficiaries, a similar pattern of diseases across 
age groups was observed. However, pregnancy-related 
conditions played a more significant role among benefi-
ciaries between 20 and 40 years of age, and musculoskel-
etal conditions played a more significant role in several 
age groups than they did among top 1% beneficiaries.
DIscussIOn
In this study, we determined medical needs, demographics 
and utilisation patterns of high-cost beneficiaries in the 
Netherlands. Expensive treatments, most cost-incurring 
condition and age proved to be informative variables for 
studying this heterogeneous population. We found that 
expensive care use (expensive drugs, ICU treatment, dial-
ysis, transplant care and DRG >€30 000) contributed to 
high costs in one third of top 1% beneficiaries and in less 
than 10% of top 2%–5% beneficiaries. High-cost benefi-
ciaries were overwhelmingly treated for diseases of circu-
latory system, neoplasms and mental disorders. However, 
neoplasms and mental disorders were mainly found as 
most cost-incurring condition for a beneficiary, whereas 
circulatory disorders were mainly found as secondary 
condition. More than 50% of high-cost beneficiaries were 
65 years of age or younger, and average costs decreased 
sharply with higher age within the top 1% population. 
Such insights are needed to develop tailored interven-
tions and inform policy aimed at the high-need, high-cost 
populations.
strengths and limitations
This was the first study assessing utilisation patterns of 
high-cost beneficiaries in a European universal health 
system, and we used innovative variables to examine char-
acteristics and utilisation. We used data from one health 
insurer with a market share of approximately 27%, with 
data representative for the Dutch population. Despite the 
limited number of variables, our data allowed detailed 
identification of healthcare use and categorisation of 
costs towards conditions. We chose to use expensive treat-
ments, most cost-incurring condition and age as variables 
for further analyses as such analyses were lacking in the 
literature, and we regarded these as most informative for 
policy and practice. One limitation is that our analysis 
was restricted to 1 year only. Consequently, we could not 
discern persistent high-cost users from episodic high-cost 
users (those with single a high-cost event5).
reflections on our findings
Our findings generally align with prior research on high-
cost beneficiaries. Similar to US studies,12 22 we identified 
three main subgroups of high-cost beneficiaries with 
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cardiovascular diseases, mental disorders and neoplasms, 
as well as several smaller subgroups. In addition, our 
findings confirm that high-cost beneficiaries are usually 
treated for several conditions and use care from multiple 
providers.10 Like prior studies,12 22 we reported a high 
prevalence of diabetes, but this condition had a limited 
direct cost impact. This may be explained by the fact that 
Dutch diabetic care is primarily situated in primary care. 
Moreover, complications of diabetes were aggregated to 
the particular condition (eg, retinopathy) using our link 
table. Furthermore, in line with Aldridge and Kelley,5 we 
found that dying increases the risk for high costs (data 
not shown) but that less than 10% of high-cost benefi-
ciaries were in their last year of life. However, we also 
found that 64% of those dying did not incur high costs, 
compared with 80% of decedents in the USA who did 
incur high costs.5 This may be explained by decedents 
that could have used long-term care services that were not 
included in our analyses. However, this may also result 
from the general practitioner-oriented organisation of 
palliative care in the Netherlands, which is known for its 
low costs.23 24
Our study is unique in estimating the relative contri-
bution of expensive treatments in high-cost beneficiaries. 
The findings indicate that high unit costs for selected 
services play a substantial role in high-costs beneficiaries. 
We identified expensive treatment users among expensive 
patients. Furthermore, our analyses show expensive treat-
ment users may use a lot of care besides such expensive 
treatments, suggesting that better alignment of expensive 
treatments with other care may be worthwhile. In line 
with Joynt et al22, we suggest that expensive procedures 
(including orthopaedic surgery, pacemaker implantation 
and so on) and catastrophic events may be a more signif-
icant cost driver in high-cost beneficiaries than avoidable 
hospitalisations and that a complementary approach (see 
below) in high-need high-cost programmes is needed.
To our knowledge, we are the first that have distin-
guished the most cost-incurring versus secondary condi-
tions in high-cost beneficiaries. For example, diseases 
of circulatory system were mainly found as a secondary 
condition, though they also frequently occurred as most 
cost-incurring condition. In addition, mental disorders 
and neoplasms were predominantly the most cost-incur-
ring condition. Our findings contribute to the rapidly 
evolving field of multimorbidity and patterns of health-
care use. We suggest that conditions that were frequently 
and primarily found as most cost-incurring condition 
should be priorities for policies that seek to contain costs 
and improve quality of care. However, the observational 
nature of our study does not allow for causal inference; 
that is, the high number of morbidities in patients with 
cancer may either indicate the many complications from 
cancer treatment or point to prior chronic disease in 
patients with cancer.
Many high-cost beneficiaries were 65 years of age 
or younger; and the average costs decreased sharply 
with increasing age within the top 1% beneficiaries. In 
addition, we found typical care needs and utilisation 
per age group. Both findings have rarely been reported 
in literature10 and underline the need for studies in the 
general population with comprehensive data. Further-
more, high-need, high-cost programmes need to be 
aimed at beneficiaries of all ages; a mere focus on elderly 
would leave many high-cost beneficiaries unaddressed.
Policy and research implications
Our findings suggest a need for approaches that address 
patients’ care needs across multiple conditions and to 
integrate care use across multiple providers. Important 
policy questions remain concerning the breadth of 
healthcare delivery innovations (ie, care coordination 
programmes, bundled payments and what should a 
bundle encompass?).25 We suggest that high-need, high-
cost programmes may aim to align the usual care for most 
cost-incurring conditions with the care for associated or 
common secondary conditions in specific care pathways. 
Furthermore, based on our findings, we recommend 
a complementary approach geared towards expensive 
procedures and drugs as well as the extensive additional 
care besides expensive treatments. This suggests bundled 
payments may be worthwhile, as well as multidisciplinary 
assessment of patients’ care needs for expensive treat-
ments. In addition, prices for expensive drugs or proce-
dures could be lowered, for example, through reference 
pricing or competitive bidding.26 27
Our research provides a precise picture of high-cost 
beneficiaries, but further research is necessary to specify 
characteristics and utilisation of high-cost beneficiaries 
at a local level. Patient segmentation analysis has been 
suggested as a method for identifying homogenous target 
population groups from diverse populations, which 
allows for tailored policies.28 Our analyses may inform 
such segmentation analyses. Furthermore, we suggest 
research into longitudinal patterns of multimorbidity to 
identify relevant subgroups that benefit from interven-
tion. More research is needed to identify beneficiaries at 
risk of incurring high costs.29
In conclusion, our findings show that high-cost bene-
ficiaries are usually treated for several conditions and 
use care from multiple providers. Expensive treatments, 
the most cost-incurring condition and age proved to be 
informative variables for studying this heterogeneous 
population. Tailored interventions are needed to meet 
the needs of high-cost beneficiaries and to avoid waste of 
scarce resources.
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